Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Spregledana korist neoadjuvantne kemoterapije v zdravljenju mišično invazivnega raka sečnega mehurja
Authors:Žist, Andrej (Author)
Milanez, Tomaž (Author)
Škrbinc, Breda (Author)
Zadnik, Vesna (Author)
Šeruga, Boštjan (Author)
Language:Slovenian
Tipology:1.01 - Original Scientific Article
Organisation:Logo OI - Institute of Oncology
Abstract:Rak sečnega mehurja predstavlja tretji najpogostejši malignom genitourinarnega trakta, incidenca in umrljivost za rakom sečnega mehurja pa sta v Sloveniji v porastu. V radikalnem zdravljenju mišično invazivnega raka sečnega mehurja je ključnega pomena lokoregionalno zdravljenje, bolniki pa so lahko deležni tudi dodatnih koristi od sistemskega zdravljenja s kemoterapijo. Klinične raziskave faze III so pokazale pomembno podaljšanje skupnega preživetja bolnikov, ki so bili zdravljeni s kombinirano neoadjuvantno kemoterapijo na osnovi cisplatina. Kljub njeni jasno dokazani učinkovitosti se neoadjuvantna kemoterapija v vsakodnevni klinični praksi širom po svetu ni uveljavila v zadostni meri. Vsak bolnik z mišično invazivnim rakom sečnega mehurja, ki je zdravljen z namenom ozdravitve in je kandidat za sistemsko zdravljenje, bi moral biti seznanjen z možnostjo zdravljenja z neoadjuvantno kemoterapijo.
Keywords:neoadjuvantna kemoterapija, rak sečnega mehurja, cistektomija
Year of publishing:2012
COBISS_ID:1421435 Link is opened in a new window
UDC:616.62-006.6-085
ISSN on article:1408-1741
OceCobissID:65324032 Link is opened in a new window
URN:URN:NBN:SI:doc-5WH5FIJC
Note:BSDOCID167389;
Views:1539
Downloads:319
Files:.pdf PDF - Presentation file, download (281,24 KB)
 
Journal:Onkologija
Onkološki inštitut
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:by Authors
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:An overlooked benefit of neoadjuvant chemotherapy in the treatment of muscle-invasive cancer of the urinary bladder
Abstract:Urinary bladder cancer is the third most frequent malignancy of the genitourinary tract, and its incidence and mortality have been increasing in Slovenia. Loco-regional treatment is key in radical treatment of the muscle-invasive cancer of the urinary bladder, and systemic chemotherapy treatment may provide additional benefits to the patients. Phase III clinical trials have demonstrated a significant prolongation of the overall survival of patients treated with neoadjuvant cisplatin-based combination chemotherapy. However, neoadjuvant chemotherapy has not yet been established sufficiently in everyday clinical practice, despite its clearly demonstrated effectiveness. Every patient with muscle-invasive cancer of the urinary bladder, who is receiving treatment with a curative intent and is a candidate for systemic treatment, should be informed of the possibility of receiving neoadjuvant chemotherapy treatment.t

Archive

niGradiv

Back